the market?
Spectrum Pharmaceuticals, Inc.
NASDAQ: SPPI
8.27
0.12
(1.47%)
| Today's Open | $8.24 |
|---|---|
| Previous Close | $8.15 |
| Daily Range | $8.05 - $8.30 |
| 52-Week Range | $6.92 - $17.48 |
| Market Cap | $496.4M |
| P/E Ratio | 11.64 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 671,783 |
| Average Daily Volume | 922,559 |
| Current FY EPS | -$0.08 |
How do you think SPPI
will perform against the market?
Top SPPI Bull/Bear Pitches
mdriver78 (2.83)
Submitted
February 16, 2011
Perhaps the FDA will approve Fusilev for mCRC on or before April 29, 2011. With FDA approval and full reimbursement, it is believed that many doctors will gravitate towards Fusilev. Here's why: Reli … More
zzlangerhans (< 20)
Submitted
May 3, 2011
As expected, Spectrum's share price rose as much as 12% today on an expected FDA approval of Fusilev for colorectal cancer, which was already pretty much written into the share price. Spectrum at a 50 … More
News & Commentary
3 Reasons You Shouldn't Buy Stocks in Biotech
Wondering if you should buy stocks in biotech? Here are 3 reasons why you might want to take a pass.Spectrum Pharmaceuticals to Present Corporate Update at the Goldman Sachs 34th Annual Global Healthc
Spectrum Pharmaceuticals Announces Positive Data from the BELIEF Trial Presented at the 2013 America
Spectrum Pharmaceuticals Highlights Six Abstracts of Clinical Data at the 2013 American Society of C
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2013 Global Healthcare Confere
Sector
Healthcare
Industry
Drugs
Spectrum Pharmaceuticals, Inc. (SPPI) Description
A biopharmaceutical company that acquires and advances a diversified portfolio of drug candidates, with a focus on oncology, urology and other critical health challenges for which there are few other treatment options. Website: http://www.sppirx.com/
CEO Rating by Glassdoor
More details for Spectrum Pharmaceuticals Jobs
Spectrum Pharmaceuticals reviews from employees
